In a quarter which saw its peers struggle, Aurobindo Pharma put out a strong March quarter performance. The company saw a 30.7 per cent growth in revenues, led by a strong 42.7 per cent growth in US sales.
The geography is its single largest, accounting for 47 per cent of overall revenues. This was largely driven by the higher margin injectables business growth, with a ramp-up in antibacterial Ertapenem injection and new launches. The company launched 15 products, including four injectables in the fourth quarter of 2018-19 (FY19). Aurobindo also completed acquisition of seven branded oncology injectable products from Spectrum